RBC Capital analyst Brian Abrahams reiterated a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT) yesterday and set a price target of $187. The company’s shares closed yesterday at $121.02.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 12.3% and a 55.5% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, Alder Biopharmaceuticals, and Intra-Cellular Therapies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $198.73 average price target, representing a 64.2% upside. In a report issued on July 26, Robert W. Baird also reiterated a Buy rating on the stock with a $202 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $176.50 and a one-year low of $35.26. Currently, Sarepta Therapeutics has an average volume of 1.59M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates.
Read More on SRPT:
